Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETNBNASDAQ:NRIXNASDAQ:SLRNNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETNB89bio$7.80-3.8%$7.24$4.16▼$11.84$1.14B1.231.36 million shs1.63 million shsNRIXNurix Therapeutics$9.73-4.4%$11.32$8.18▼$29.56$776.08M2.23889,785 shs534,374 shsSLRNAcelyrin$2.09-15.7%$2.44$1.85▼$7.25$210.90M1.071.20 million shs1.91 million shsVIRVir Biotechnology$4.70-11.3%$6.15$4.69▼$14.45$648.90M1.361.35 million shs2.56 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETNB89bio-3.82%+0.65%+41.05%-29.16%-10.34%NRIXNurix Therapeutics-4.42%+0.83%+6.46%-43.79%-30.20%SLRNAcelyrin-15.73%-13.64%-6.28%+4.50%-55.44%VIRVir Biotechnology-11.32%-16.52%-15.01%-48.41%-51.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETNB89bio3.0186 of 5 stars4.51.00.00.04.00.80.6NRIXNurix Therapeutics2.2055 of 5 stars4.41.00.00.02.60.80.0SLRNAcelyrin2.751 of 5 stars3.22.00.00.02.23.31.3VIRVir Biotechnology2.7248 of 5 stars3.41.00.00.02.43.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETNB89bio 3.00Buy$27.25249.36% UpsideNRIXNurix Therapeutics 2.84Moderate Buy$30.44212.89% UpsideSLRNAcelyrin 2.40Hold$9.60359.33% UpsideVIRVir Biotechnology 2.86Moderate Buy$32.86599.09% UpsideCurrent Analyst Ratings BreakdownLatest SLRN, ETNB, NRIX, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.005/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/29/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/9/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.004/9/2025NRIXNurix TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $35.004/9/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.004/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/2/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETNB89bioN/AN/AN/AN/A$5.75 per shareN/ANRIXNurix Therapeutics$56.42M13.15N/AN/A$7.44 per share1.31SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/AVIRVir Biotechnology$14.30M45.37N/AN/A$11.82 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%N/ANRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%N/AVIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)Latest SLRN, ETNB, NRIX, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETNB89bioN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETNB89bio0.0911.6611.66NRIXNurix TherapeuticsN/A6.466.46SLRNAcelyrinN/A7.157.15VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETNB89bioN/ANRIXNurix TherapeuticsN/ASLRNAcelyrin87.31%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipETNB89bio2.60%NRIXNurix Therapeutics7.40%SLRNAcelyrin13.60%VIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETNB89bio40145.98 million103.15 millionOptionableNRIXNurix Therapeutics30076.24 million70.42 millionOptionableSLRNAcelyrin135100.91 million86.68 millionOptionableVIRVir Biotechnology580138.06 million116.24 millionOptionableSLRN, ETNB, NRIX, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Price Target Cut to $14.00 by Analysts at Needham & Company LLCMay 13 at 1:56 AM | americanbankingnews.comVir’s hepatitis B combo falls short in Phase II trialMay 12 at 10:46 PM | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12 at 4:05 PM | businesswire.comBridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)May 12 at 4:46 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LPMay 11 at 3:51 AM | marketbeat.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comDAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)May 10, 2025 | marketbeat.comWhy Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%May 10, 2025 | aaii.comQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir's 'functional cure' candidate for hepatitis B misses mark in phase 2May 10, 2025 | fiercebiotech.comVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comVir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virusMay 8, 2025 | msn.comVir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...May 8, 2025 | uk.finance.yahoo.comVir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | businesswire.com1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LPMay 6, 2025 | marketbeat.comWells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)May 6, 2025 | marketbeat.comBarclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRN, ETNB, NRIX, and VIR Company Descriptions89bio NASDAQ:ETNB$7.80 -0.31 (-3.82%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$7.85 +0.05 (+0.64%) As of 08:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Nurix Therapeutics NASDAQ:NRIX$9.73 -0.45 (-4.42%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$10.24 +0.51 (+5.24%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Acelyrin NASDAQ:SLRN$2.09 -0.39 (-15.73%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$2.11 +0.02 (+0.91%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Vir Biotechnology NASDAQ:VIR$4.70 -0.60 (-11.32%) Closing price 05/13/2025 04:00 PM EasternExtended Trading$4.83 +0.13 (+2.77%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? ON Holding Surges, Leads High-End Retailers Into Reversal NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
